Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-25

Study Completion Date

2021-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of \[14C\]-BLU-5937.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371

NCT04649216

Healthy Volunteers

COMPLETED PHASE1

Mass Balance Study With MT-8554

NCT03381404

Healthy Volunteer

COMPLETED PHASE1

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

NCT04952467

Healthy Volunteers

COMPLETED PHASE1

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

NCT06645704

Healthy Participants

COMPLETED PHASE1

Mass Balance Study of KBP-5074 in Healthy Male Subjects

NCT04634812

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Single oral dose of \[14C\]-BLU-5937

Group Type EXPERIMENTAL

[14C]-BLU-5937

Intervention Type DRUG

Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[14C]-BLU-5937

Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males

Exclusion Criteria

* History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder,as judged by the investigator

Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes